#Neurobiology @thelancet #Atogepant 30 mg twice a day and 60 mg once a day showed clinically relevant reductions in monthly #migraine days across 12 weeks in chronic migraine patients. Both atogepant doses were well tolerated, consistent with the known safety profile of atogepant.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01049-8/fulltext?utm_campaign=trials23&utm_content=263103929&utm_medium=social&utm_source=twitter&hss_channel=tw-27013292